carbimazole
Carbimazole (brand names Neo-Mercazole, Anti-Thyrox, etc.) is used to treat hyperthyroidism. Carbimazole is a pro-drug as after absorption it is converted to the active form, methimazole. Methimazole prevents thyroid peroxidase enzyme from iodinating and coupling the tyrosine residues on thyroglobulin, hence reducing the production of the thyroid hormones T3 and T4 (thyroxine). — Wikipedia
Clinical trial activity
3 trials · 8 clinical orgs · 0 marketing orgs
Earliest trial started Aug 1, 2003 (NCT00430547)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Thyroid peroxidaseINHIBITOR
TPO inhibitor
Carbimazole is a prodrug as after absorption it is converted to the active form, methimazole. Methimazole prevents thyroid peroxidase enzyme from coupling and iodinating the tyrosine residues on thyroglobulin, hence reducing the production of the thyroid hormones T3 and T4.
Chemistry & pharmacology
SMILES
CCOC(=O)n1ccn(C)c1=S- Mol. weight
- 186.24 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCarbimazole ↗
- ChEMBLCHEMBL508102 ↗
Also known as
- 1h-imidazole-1-carboxylic acid, 2,3-dihydro-3-methyl-2-thioxo-, ethyl ester ethyl 3-methyl-2-thioimidazoline-1-carboxylate
- 1h-imidazole-1-carboxylic acid, 2,3-dihydro-3-methyl-2-thioxo-, ethyl ester ethyl 3-methyl-2-thioimidazoline-1-carboxylate
- athyromazole
- athyromazole
- athyromazole
- athyromazole
- carbethoxymethimazole
- carbethoxymethimazole
- carbethoxymethimazole
- carbimazol
- carbimazol
- carbimazol
- carbimazole
- carbimazole
- carbimazole
- carbimazole
- carbimazole
- carbimazole
- carbimazole
- carbimazole
- carbimazole
- carbimazolo
- carbimazolo
- carbimazolum
- carbimazolum
- carbinazole
- carbinazole
- ethyl 3-methyl-2-thioimidazoline-1-carboxylate
- ethyl 3-methyl-2-thioimidazoline-1-carboxylate
- neomercazole
- neo-mercazole 20
- neo-mercazole 5
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03064542 | N/A | Jun 1, 2017 | Agency for Science, Technology and Research, Nanyang Technological University, National University of Singapore |
| NCT01436994 | Phase 3 | Jul 1, 2004 | Newcastle University |
| NCT00430547 | N/A | Aug 1, 2003 | Barwon Health, National Health and Medical Research Council, Australia, University of Melbourne, University of Sydney |
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Agency for Science, Technology and Research | Government | 1 | 0 | 1 | 2017 |
| Barwon Health | Academic/Hospital | 1 | 1 | 1 | 2003 |
| Nanyang Technological University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| National Health and Medical Research Council, Australia | Government | 1 | 0 | 1 | 2003 |
| National University of Singapore | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Newcastle University | Academic/Hospital | 1 | 1 | 1 | 2004 |
| University of Melbourne | Academic/Hospital | 1 | 0 | 1 | 2003 |
| University of Sydney | Academic/Hospital | 1 | 0 | 1 | 2003 |